Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Details : Tilray's oral solution THC10:CBD10 medical cannabis extract is approved for medical use in Portugal for various medical conditions including chronic pain, nausea and spasticity.
Product Name : THC10:CBD10
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 24, 2024
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tilray Medical Shares Positive Oral Cannabis Extract Data for Chemotherapy-Induced Emesis
Details : Tilray Medical aimed to test the effectiveness of an oral cannabis extract in adults suffering from chemotherapy-induced nausea and vomiting despite standard anti-nausea treatments.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tilray Medical Launches New Products and ‘CannaPoints’ Program to Support Patients Across Canada
Details : Tilray Medical, has released new medical cannabis products, under Tilray and Aphria brands and launched CannaPoints, a new program designed to support patients through their medical cannabis journey.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 25, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tilray Medical Launches Sleep-Oriented CBN Night Oil for Medical Cannabis Patients in Canada
Details : CBN, or cannabinol, is derived from THC and is known to help improve the duration and quality of sleep, CBN-dominant oil is carefully formulated with 30mg CBN per mL and 10mg THC per mL (in a 50mL bottle).
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Aphria
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company's Fast-Acting Oral Strips contain Cannabinoids absorb directly into the bloodstream provide patients with a fast-acting, convenient, and precise dosing experience for relief from a range of conditions.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 12, 2021
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Aphria
Deal Size : Inapplicable
Deal Type : Inapplicable